Vinita D. Gupta
Known title: DirectorCIK: 0001705209
Associated companies
Transaction History
| PGEN | ▲ Buy | Option Exercise | 71,839 | — | 3/13/2026 | View on chart |
| PGEN | ▲ Buy | Grant | 17,948 | $63K | 3/10/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 87,412 | — | 3/14/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 36,206 | $63K | 3/13/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 44,055 | $63K | 3/14/2024 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 106,837 | — | 3/9/2024 | View on chart |
| PGEN | ▲ Buy | Grant | 48,290 | $56K | 3/9/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 61,576 | — | 2/22/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 16,212 | — | 3/25/2022 | View on chart |
| PGEN | ▲ Buy | Grant | 27,832 | $56K | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.